132 related articles for article (PubMed ID: 20147576)
1. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
3. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
4. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
9. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect?
Adams CB; Street DS; Crass M; Bossaer JB
J Oncol Pharm Pract; 2016 Dec; 22(6):784-789. PubMed ID: 26590031
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
Cao Y; Liao C; Tan A; Liu L; Gao F
Chemotherapy; 2010; 56(6):459-65. PubMed ID: 21088398
[TBL] [Abstract][Full Text] [Related]
12. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested case-control in a retrospective cohort study.
Ramírez E; Cabañas R; Laserna LS; Fiandor A; Tong H; Prior N; Calderón O; Medrano N; Bobolea I; Frías J; Quirce S
Clin Exp Allergy; 2013 Mar; 43(3):344-52. PubMed ID: 23414543
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
15. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
16. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center.
Burke E; Rockey M; Grauer D; Henry D; Neupane P
Med Oncol; 2017 Apr; 34(4):51. PubMed ID: 28229341
[TBL] [Abstract][Full Text] [Related]
18. Incidence of amiodarone hypersensitivity in patients with previous allergy to iodine or iodinated contrast agents.
Lakshmanadoss U; Lindsley J; Glick D; Twilley CH; Lewin JJ; Marine JE
Pharmacotherapy; 2012 Jul; 32(7):618-22. PubMed ID: 22605538
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of premedication, glucocorticosteroids, and H
Ikegawa K; Suzuki S; Nomura H; Enokida T; Yamazaki T; Okano S; Endo K; Saito S; Yamaguchi M; Tahara M
J Int Med Res; 2017 Aug; 45(4):1378-1385. PubMed ID: 28606015
[TBL] [Abstract][Full Text] [Related]
20. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms.
Piovano E; Pivetta E; Modaffari P; Martra F; Baima Poma C; Perotto S; Tripodi E; Zanfagnin V; Zola P; Ferrero A
Gynecol Obstet Invest; 2012; 74(1):21-7. PubMed ID: 22652565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
